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RA associated with oxidative stress and chronic inﬂammation has been a major health problem among
the population worldwide. In this study protective effect of methanolic extract of Adhatoda vasica leaf
(AVE) was evaluated on Collagen-induced arthritis in male Swiss albino mice. Post oral administration of
AVE at 50, 100 and 200 mg/kg body weight doses decreased the arthritic index and footpad swelling. AVE
administration diminished pro-inﬂammatory cytokines in serum and synovial tissues. Reduced che-
mokines and neutrophil inﬁltration in synovial tissues after AVE administration dictated its protective
effect against RA. Decreased LPO content and SOD activity along with concomitant rise in GSH and CAT
activities from liver, spleen and synovial tissues indicated regulation of oxidative stress by AVE. In
addition decreased CRP in serum along with suppressed TLR-2 expression in CIA mice after AVE treat-
ment was also observed. Protective effect of AVE in RA is further supported from histopathological
studies which showed improvement during bone damage. In conclusion this study demonstrated
A. vasica is capable of regulating oxidative stress during CIA and therefore down regulated local and
systemic release of pro-inﬂammatory mediators, which might be linked to mechanism of decreasing
synovial TLR-2 expression via downregulating release of its regular endogenous ligands like CRP.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).T, Catalase; CFA, Complete
X-2, Cyclooxygenase-2; CRP,
ic acid; ELISA, Enzyme linked
a; GSH, Reduced glutathione;
adjuvant; IFN-g, Interferon




sphate buffer saline; PMN,
diﬂuorides; RA, Rheumatoid
ogen species; ROS, Reactive
rum glutamate oxaloacetate
rase; SLE, Systemic lupus er-
Thiobarbituric acid reactive
eptor; TNF-a, Tumor necrosis
hydrochloric acid.
, Immunology and Microbi-
olleges of Science and Tech-
India.
Bishayi).
r Inc. This is an open access article1. Introduction
Rheumatoid arthritis (RA) is an autoimmune disease affecting
about 1e2% of theworld's population [1], characterized by systemic
and irreversible destruction of the cartilage, tendons and bone
initiated upon deposition of autoimmune complexes into synovial
joint spaces. However the factors responsible for development of
RA are not clear, genetic polymorphisms and environmental factors
were mentioned to contribute in RA pathogenesis [2]. Chronic
inﬂammation during RA is associated with severe oxidative stress
and inﬂammatory reactions into joints and other tissues [3],
therefore agents with anti-inﬂammatory and anti-oxidant poten-
tials will possess obvious means of their use against RA [4].
Existing treatment options in RA includes targeting of different
molecules on B-cells, e.g. rituximab, ocrelizumab and veltuzumab;
targeting cytokines by means of speciﬁc monoclonal antibodies,
but many of them has been banned for their disadvantageous ef-
fects [5]. A number of different anti-inﬂammatory drugs have also
been introduced such as naproxen, salsalate, tolmetin and NSAIDS,
blockers of COX-2, which also possess potential side effects [6].
Antioxidant supplement has been suggested as alternateunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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mentioned in many studies [7,8].
Application of natural products has been potential remedies in
treatment of RA in the old practice of traditional medicinal system.
A. vasica Nees, the acanthaceae is a medicinal herb that is being
used in indigenous system for several hundred years and is
considered as an ofﬁcial drug in Pharmacopoeia, India, 1994.
Antioxidant properties in different parts of this plant have been
well documented in a number of studies [9]. Anti-inﬂammatory
potential of pyrroloquinazoline alkaloids from this plant has been
shown against adjuvant-induced experimental arthritis in mice
[10]. Since RA is a chronic inﬂammatory disease, associated with
oxidative stress and inﬂammatory reactions initiated by a complex
network of signaling, treatment with a natural extract containing
an array of important bio-active molecules will obviously possess
beneﬁcial effect over the use of any isolated and puriﬁed
compound.
Involvement of the components of innate immune system al-
ways have been interesting in the area of rheumatology and were
investigated for their roles in rheumatoid arthritogenesis [11,12].
Toll like receptors (TLRs) are molecules of innate immune system,
present on the surfaces of macrophages and dendritic cells that are
critical for generation of B and T lymphocyte responses under
conditions of pathogenic invasion [13]. In recent years, studies on
the involvement of TLR-2 in many auto-immune diseases like SLE
(Systemic lupus erythematosus) and RA has implicated crucial role
of many TLRs in pathogenesis of these autoimmune diseases [14].
Among eleven different subtypes, expression of TLRs, 2, 3, 4
and7 have been found in RA synovium frommice, indicating their
possible involvement in pathogenesis of RA [15,16]. Apart from the
microbial products which are conventional ligands for TLR-2, there
are different endogenous molecules expressed within cells at the
time of chronic inﬂammation under conditions of stress, apoptosis
and tissue necrosis e.g., heat shock proteins 60 and 70, ﬁbrin-
ogen, ﬁbronectin, hyaluronic acid, tenascin-C. Therefore whether
AVE affects the TLR-2 expression in synovial tissues was an obvious
question.
The aim of this study was to evaluate anti-arthritic potential of
A. vasica against auto-immune arthritis in Swiss albino mice, using
collagen-induced arthritis (CIA) model. Effect of the methanol
extract of A. vasica in inﬂammatory response during CIA was
studied by measuring CRP, different cytokines in serum and syno-
vial tissue and by assessment of neutrophil accumulation in spleen
and synovial tissues. Level of GSH, TBARs, NO and enzymatic ac-
tivities of SOD and CAT in liver, synovial tissue and spleen was
determined to assess the effect of the A. vasica extract in neutral-
izing oxidative stress during CIA. Immunoblotting experiment has
been performed to determine whether AVE has any impact on the
changes in TLR-2 expression in synovial tissue during CIA.
2. Materials and methods
2.1. Plant collection and preparation of extract
Whole A. vasica plants were collected from Singur in West
Bengal, India. Botanical identiﬁcation of the samples was conﬁrmed
taxonomically by The Botanical Survey of India, Ministry of Envi-
ronment and Forest, Govt. of India, [Ref No. CNH/50/2014/Tech.II/
103]. 10 g of dried, ﬁnely ground leaves were soaked into 30 ml of
70% methanol at 30 C for 12 h with shaking and the methanol was
then allowed to evaporate completely (under sterile conditions)
and was ﬁltered with Whatman's #1 ﬁlter paper. It was repeated
thrice and ﬁnally the ﬁltrate was centrifuged at 2000 rpm for
10 min. The supernatant collected was treated with charcoal for
decolorization and was then air-dried to completeness understerile conditions. The yield was 7.1% (7.1 g powdered extract/100 g
dried ﬁnely-ground leaf). The powdered from of the extract was
dissolved into sterile PBS.
2.2. Experimental animalsþ
Male Swiss-Albino mice (20e22 g, 3e4 weeks of age) obtained
from the Chittaranjan National Cancer Institute, Kolkata, Indiawere
used in this study. All the animals were housed in separate poly-
styrene cages in pathogen-free facilities maintained at 25 [±2] C,
with 50e60% relative humidity, and 12 h light: dark cycle. All mice
had ad libitum access to normal laboratory diet (NLD) that consisted
of 22.5% wheat ﬂour, 60.0% roasted Bengal-gram ﬂour, 5.0% skim-
med milk powder, 4.0% casein, 4.0% reﬁned groundnut oil, 4.0% salt
mixture and 0.5% vitamin mixture, as recommended for mice, by
the National Center for Laboratory Animal Sciences, National
Institute of Nutrition, India and ﬁltered tap water. All experiments
involving animals were conducted according to the protocols
approved by Institutional Animal Ethics Committee (IAEC),
Department of Physiology, University of Calcutta, under the guid-
ance of CPCSEA [Approval# IAEC/IV/Proposal/BB-2/2014, dated 26-
08-2014], Ministry of Environment and Forest, Government of In-
dia. The animals were divided into six experimental groups, each of
which containing six mice (n ¼ 36), i.e., NLD fed control group, AVE
(100 mg/kg) fed group, CIA group, CIA þ AVE (50 mg/kg) fed group,
CIA þ AVE (100 mg/kg) fed group and CIA þ AVE (200 mg/kg) fed
group.
2.3. Dosage of plant extracts
The doses of plant extract used in this study were determined
from oral acute toxicity study. AVE at 500, 750, 1000, 1500, 2000, or
2500 mg/kg body weight doses were administered to mice p.o.
Doses up to 2000 mg/kg did not cause death or behavioral changes
upto 72 h. According to earlier studies 1/20th of this dose, i.e.,
100 mg/kg, was considered as the safe dose for this study [17]. To
bracket this value, doses of 50 and 200 mg/kg were also selected as
the dose regimen in this study.
2.4. Preparation of type II collagen emulsion for immunization
Lyophilized bovine type II collagen (Sigma, St. Louis, MO) was
dissolved in 0.05 M acetic acid solution at 2 mg/ml concentration.
An equal volume of Freund's complete adjuvant was then added
and the solution was emulsiﬁed slowly [18]. The booster dose was
prepared by emulsifying type II collagen with equal volume of
Freund's incomplete adjuvant.
2.5. Immunization and treatment
Mice were immunized subcutaneously at the base of the tail
with 100 ml of type II collagen-CFA emulsion, and all the mice were
provided normal laboratory diet for 20 days. At day 21 after the
primary immunization, the mice were again immunized with
100 ml of type II collagen in IFA [18]. The mice were then carefully
monitored for onset of early signs of arthritis, i.e., redness/de-
formities/swelling in the joints and/or toes, etc. After the secondary
immunization AVE was administered per orum daily in a volume of
200 ml (animals from the control group received only sterile PBS)
from the date of onset of ﬁrst signs of arthritis (i.e., day 25 after
primary immunization), routinely up to day 41 of the experiment
(i.e., 20 days after secondary immunization). On day 45 after the
primary immunization, all mice were euthanized using ether. The
precise protocol by which animal experiment was conducted
including administration of CIA, treatment with AVE and the whole
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2.6. Assessment of arthritic scores and joint swelling
Mice were monitored for signs of arthritis for which severity
scores were derived as: 0 ¼ no signs of arthritis; 1 ¼ swelling/
redness in only one joint; 2 ¼ swelling/redness in more than one
joint; 3 ¼ swelling/redness in entire paw; 4 ¼ severe swelling of
entire paw with deformity and/or ankylosis. The macroscopic
arthritic score of each mouse was presented as the sum of each
score of the four limbs, with the maximum score being 16 for all
four limbs. Footpad swelling was evaluated by measuring the
thickness of the two hind pawswith an electric digital caliper every
other day beginning on day 21 after primary immunization (i.e. day
4 after secondary booster immunization). On day 45 after the ﬁrst
immunization, all mice were euthanized for analysis.
2.7. Collection of blood and tissue samples
Immediately after being euthanized, blood samples were ob-
tained from each mouse by cardiac puncture. The blood samples
were then placed at 4 C for 45 min and then centrifuged at
3000 rpm for 5 min at 4 C. The serum was collected as the pale
white yellow colored supernatant, aliquots were assessed for total
protein levels using Bradford's method [19], and the remaining
aliquots were stored at 20 C for later analysis. Liver, spleen and
synovial joints from the hind and fore limbs were then collected
from each animal and stored at20 C for use in later experiments.
2.8. Histopathological analysis of synovial joints
Histopathological analyses of the isolated synovial joints were
carried out [20]. Knee joints isolated at necropsy were ﬁxed
immediately for 2 h in 4% paraformaldehyde and then de-calciﬁed
with 10% EDTA at 4 C. The samples were then embedded in
parafﬁn, sections were prepared (at 6.0 mm thickness), and the
tissues were then stained with hematoxylin and eosin prior to
analysis using a light microscope.
2.9. Serum glutamate oxaloacetate transferase (SGOT) and
glutamate pyruvate transferase (SGPT) activity measures
An aliquot (100 ml) of serum was mixed with 0.5 ml SGOT andSGPT substrates and incubated with serum and were allowed to
react with 2,4-DNPH solution and another incubation were fol-
lowed by addition of 0.4 (N) NaOH solution [21]. The intensity of the
developed color was read at 540 nm. The SGOT and SGPT activities
were expressed in IU/ml of serum.
2.10. Assessment of serum CRP level
Concentrations of CRP in serum were determined using a
commercial sandwich ELISA kit (My Biosource, San Diego, CA) ac-
cording to manufacturer instructions, with ﬁnal absorbance values
being measured using a microplate reader (BioRad, Hercules, CA).
Values of CRP in samples were extrapolated from a standard curve
prepared in parallel. All values were reported as ng CRP/ml serum.
The level of sensitivity of the kit was 2000 ng CRP/ml.
2.11. Assessment of TNF-a, IFN-g, IL-1b, IL-6, IL-12, and IL-10 from
serum and synovial joints
Synovial joints were lysed in lysis buffer (containing 300 mM
NaCl, 15 mM Tris [pH 7.4], 2 mM MgCl2, 2 mM Triton X-100, 20 ng
pepstatin A/ml, 20 ng leupeptin/ml, and 20 ng aprotinin/ml) and
then centrifuged at 2900 rpm for 15 min at 4 C; the supernatants
were kept at 20 C until use. The homogenates and serum were
normalized for protein content by Bradford's method. Concentra-
tions of pro-inﬂammatory cytokines tumor necrosis factor (TNF)-a,
interferon (IFN)-g, interleukin (IL)-1b, IL-6, and IL-12, as well as of
anti-inﬂammatory IL-10, were determined using commercial kits
(RayBiotech, Inc., Norcross, GA) according to manufacturer in-
structions. Levels for each cytokine in a sample were extrapolated
from standard curves prepared in parallel. All values were reported
as ng cytokine/ml serum. The levels of sensitivity of the kits were
60 pg TNFa, 5 pg IFNg, 5 pg IL-1b, 2 pg IL-6, 5 pg IL-12, and 45 pg IL-
10 respectively.
2.12. Assessment of chemokines like IL-8 and MCP-1 in synovial
joints
Concentrations of IL-8 (My Bio Source) and MCP-1(Ray Biotech
Inc) were determined from synovial joint homogenates using
commercial ELISA kits. The experiments were performed according
to the manufacturer's instructions. The levels of sensitivity of these
kits were 2 ng IL-8, and 3 pg MCP-1 respectively.
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and synovial joints
MPO activity was analyzed to reﬂect neutrophil (PMN) inﬁltra-
tion into tissues, as it is closely related to the number of PMN
present. Spleen and synovial tissues isolated from mouse after
sacriﬁce were homogenized with 20 mM TriseEDTA-HCl (pH 7.0)
buffer supplemented with sucrose and protease inhibitor cocktail.
Homogenate was mixed with 10 mM potassium phosphate buffer,
o-dianisidine dihydrochloride (0.167 mg/ml) and 0.005% H2O2;
MPO activity was measured at 405 nm [22].
2.14. Assessment of anti-oxidant status in different tissues
Liver, spleen, and synovial tissues were separately homogenized
on ice for 30 s using a Polytron homogenizer with ice cold 50 mM
potassium phosphate buffer (pH 7.4). Homogenates were centri-
fuged at 9000 rpm for 20 min at 4 C,supernatants were collected
and aliquots were used to assess the total protein content by
Bradford method and anti-oxidant status. GSH was estimated as
acid soluble sulfhydryl content, by its reactionwith DTNB (Ellman's
reagent) in mmoles/mg of tissue protein [23]. The tissue contents of
lipid peroxidation products in tissue homogenate were determined
as the generation of thio-barbituric reactive substances in n moles/
mg of tissue protein [24]. SOD enzyme activity in tissue homoge-
nate was measured as the amount of enzyme capable inhibiting
50% oxidation of pyrogallol [25]. CAT enzyme activity in tissue
homogenate was measured as the decomposition of H2O2 in m
moles/min/mg of tissue protein [25].
2.15. Assessment of NO production in synovial joints
Nitrite concentrations in paw tissues weremeasured as an index
reﬂecting local NO production. Synovial tissues were homogenized
into ice cold 1 ml sterile PBS. After centrifugation at 12,000 rpm for
30 min at 4 C, supernatants were collected and analyzed for NO
production using a modiﬁed Griess method, as described earlier
[26]. The amounts of NO produced were determined by extrapo-
lation from a standard curve prepared in parallel using sodium
nitrite.
2.16. Immunoblot analysis for TLR-2 expression in synovial tissue
Synovial joints isolated during euthanasia from different groups
of mice were lysed with RIPA buffer, supplemented with Nonidet P-
40. 60 mg of tissue lysate was removed, denatured at 100 C for
5 min, resolved by 10% SDS-PAGE, and then electro-transferred
onto nitrocellulose membranes. After blocking for 2 h at 4 C in
TBST (20 mM TriseHCl [pH 7.4], 150 mM NaCl, 0.1% Tween 20),
containing 5% BSA, the membrane was washed thrice in TBST and
probed overnight at 4 C with anti-mouse-TLR-2 antibody (1:400
dilution; Biorbyt Ltd., Cambridgeshire, UK) in TBST, supplemented
with 1% BSA. Blots were then washed thrice in TBST, incubated for
2 h at 4 C with appropriate HRP-conjugated secondary antibodies
(1:5000 dilution; Biorbyt Ltd. UK). The ﬁnal signal was developed
using Super Signal-chemiluminescent-substrate (Thermo Scienti-
ﬁc, USA). Each blot was then exposed to X-Omat BT ﬁlms (Kodak,
Windsor, CO) and bands were quantiﬁed using QUANTITY ONE
software (Bio-Rad, Inc., Hercules, CA).
2.17. Statistical analysis
All data are reported as mean ± SD. Assessment of signiﬁcant
differences between groups were performed using a 1-way Anal-
ysis of Variance (ANOVA). A p-value < 0.05 was consideredsigniﬁcant. A Scheffe's F-test post-hoc test for multiple comparisons
of the different groups was done when signiﬁcant p-values were
obtained.
3. Results
3.1. Macroscopic arthritic scoring and footpad swelling in CIA mice
treated with AVE
Arthritis was induced in mice z3 weeks after primary immu-
nizationwith collagen II-CFA, i.e. 4 days after booster immunization
with collagen II-IFA. In the course of treatment with AVE, it was
observed that daily administration of the three doses of AVE, i.e., 50,
100, or 200 mg/kg, signiﬁcantly inhibited arthritic progression
(Fig. 1A and B). Maximal inhibition in arthritic scoring and footpad
swelling was observed at the day 12 after booster immunization in
the different groups of mice.
3.2. Histopathological analysis of knee joints in CIA mice treated
with AVE
Hematoxylin-eosin staining of arthritic joint sections isolated
from the mice in the various experimental groups revealed
detectable degradation in the joint synovial tissues, inﬂammation,
PMN accumulation and necrosis after collagen administration
(Fig. 2). These indices of tissue damage appeared to be attenuated
by AVE treatment at a dose of 100 mg/kg in CIA induced mice.
3.3. Effect of AVE on SGOT and SGPT concentrations
Administration of collagen II signiﬁcantly increased levels of
SGOTand SGPT, themarkers of bone erosion, in the serum in case of
CIAmice as compared to the NLD-fed control and AVE (100mg/kg)-
fed mice. All the three doses of AVE signiﬁcantly reduced the SGOT
and SGPT (Table 1) and suggesting an ability of the extract to
mitigate bone erosion at times of arthritic progression. The
reduction in the serum concentration of these enzymes was
maximumwith the 200mg/kg AVE oral administration in CIA mice.
3.4. Effect of AVE on serum CRP levels
A signiﬁcant increase in serum concentrations of C-reactive
protein (CRP) in the CIA mice challenged with type II collagen
emulsion was observed (indicating acute tissue damage) in com-
parison to outcomes noted in the NLD-fed control and AVE
(100 mg/kg)-fed mice (Table 2). Administration of the three
different doses of AVE from the day of onset of arthritic symptoms
signiﬁcantly reduced the concentration of this acute phase protein
in serum from CIA mice.
3.5. Effect of AVE on serum cytokine concentrations
The concentrations of pro-inﬂammatory TNFa, IL-1b, IFNg, IL-6,
and IL-12 were elevated in the serum of the mice challenged with
type II collagen (CIA group) as compared to the NLD and AVE-fed
groups. Treatment with AVE in CIA induced mice signiﬁcantly
decreased these cytokines in serum (Fig. 3AeE). On the other hand,
the concentrations of IL-10 (Fig. 3F), a major anti-inﬂammatory
cytokine, was reduced in CIA mice as compared to the NLD and
AVE-fed mice. Treatment with AVE have signiﬁcantly restored IL-10
level in serum from CIA mice.
3.6. Effect of AVE on synovial cytokine/chemokine concentrations
Levels of pro-inﬂammatory TNFa, IL-1b, IFNg, IL-6, and IL-12 in
Fig. 1. Macroscopic arthritic scoring (A) and footpad swelling (B) in mice in the different treatment groups. The results were obtained from three repeated experiments; values are
expressed as mean ± SD (n ¼ 6/group). *indicates signiﬁcant difference in comparison to AVE (100 mg/kg)-fed mice (p < 0.05); #indicates signiﬁcant difference in comparison to CIA
mice (p < 0.05).
Fig. 2. Histopathological analysis of knee joints. Representative photographs of H&E-stained sections (magniﬁcation 100X) from knee joints of (A) control mice, (B) AVE (100 mg/
kg)-only mice, (C) CIA mice, and (D) CIA mice treated with AVE (100 mg/kg). Cellular accumulation and epithelial damage is indicated in photographs. Arrows indicate damage in
synovial lining and epithelia.
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comparison to NLD and AVE-fed counterparts. The CIA mice also
had suppressed synovial IL-10 levels as compared to other groups.
Treatment with AVE signiﬁcantly suppressed the increases in local
concentration of the pro-inﬂammatory cytokines in synovial tis-
sues (Fig. 4AeE), and signiﬁcantly increased the level of IL-10(Fig. 4F). In addition, CIA mice showed a signiﬁcant elevation in
tissue levels of IL-8 and MCP-1, two important chemokines in the
joint synovium. A marked decrease in levels of these chemokines
was also observed with treatment of AVE (Fig. 4G and H) in CIA
mice.
Table 1
Serum concentration of SGOT (in IU/ml) and SGPT (in IU/ml).
Sl. No. Groups SGOT in IU/ml (mean ± SD) SGPT in IU/ml (mean ± SD)
1. NLD (control) 49.27 ± 6.29 19.28 ± 3.13
2. AVE (100 mg/kg) 47.29 ± 7.12 21.18 ± 3.73
3. NLD þ CIA 101.92 ± 15.29*# 58.27 ± 9.21*#
4. CIA þ AVE (50 mg/kg) 69.21 ± 9.87*#^ 34.19 ± 5.17*#^
5. CIA þ AVE (100 mg/kg) 59.27 ± 8.29 ^ 23.31 ± 3.22 ^
6. CIA þ AVE (200 mg/kg) 53.19 ± 7.33 ^ 20.19 ± 2.98 ^
Effects of AVE on SGOT and SGPT levels. Changes in the SGOT and SGPT activities in serum from the mice of all the six groups. The results were reproduced in three repeated
experiments. Values are expressed as means ± SD of six mice per group. P value less than 0.05 was considered as signiﬁcant. *indicates signiﬁcant (P < 0.05) difference in
comparison to NLD (control), #indicates signiﬁcant difference (P < 0.05) in comparison to AVE (100 mg/kg) fed mice and i^ndicates signiﬁcant difference (P < 0.05) in
comparison to CIA induced mice.
Table 2
Serum concentration of C-reactive protein (in ng/ml).
Sl. No. Groups Concentration of serum CRP in ng/ml (mean ± SD)
1. NLD (control) 124.26 ± 13.91
2. AVE (100 mg/kg) 119.32 ± 12.34
3. NLD þ CIA 141.71 ± 18.94*#
4. CIA þ AVE (50 mg/kg) 132.56 ± 21.46 ^
5. CIA þ AVE (100 mg/kg) 127.81 ± 18.57 ^
6. CIA þ AVE (200 mg/kg) 122.16 ± 19.73 ^
Effects of AVE on serum CRP levels. Concentrations of serum CRP (in ng/ml) measured from all the six groups using ELISA method. The results
were reproduced in three repeated experiments. Values were expressed as means ± SD of six mice per group. P value less than 0.05 was
considered as signiﬁcant. *indicates signiﬁcant (P < 0.05) difference in comparison to NLD (control), #indicates signiﬁcant difference (P < 0.05)
in comparison to AVE (100 mg/kg) fed mice and i^ndicates signiﬁcant difference (P < 0.05) in comparison to CIA induced mice.
Fig. 3. Serum cytokine concentrations in mice. Levels of (A) TNFa, (B) IL-1b, (C) IFNg, (D) IL-6, (E) IL-12, and (F) IL-10 in serum from mice as determined by ELISA. Results were
reproduced in three experiments. The results are obtained from three repeated experiments and the values are expressed as mean ± SD; (n ¼ 6/group). *indicates signiﬁcant
difference in comparison to NLD (control) (p < 0.05); #indicates signiﬁcant difference in comparison to AVE (100 mg/kg)-fed mice (p < 0.05); and, i^ndicates signiﬁcant difference in
comparison to CIA mice (p < 0.05).
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Myeloperoxidase activity (MPO; measure of neutrophil activa-
tion in/inﬁltration into tissues) was assessed in the spleen and sy-
novial tissues. The results indicated signiﬁcant elevation of MPO in
both tissues in the CIA mice compared to counterpart tissues from
NLD and AVE-fed groups. Treatment with AVE signiﬁcantly reduced
MPO activity in both tissues fromCIAmice, suggesting an inhibitory
effect of AVE on tissue neutrophil accumulation (Fig. 5A and B).3.8. Effect of AVE on anti-oxidant status in hepatic, splenic and
synovial tissues
GSH content as well as CAT activities were signiﬁcantly
decreased in the liver, spleen and synovial tissue in CIA mice, along
with concomitant increase in LPO content and SOD enzyme activ-
ities. Treatment with AVE at the different doses restored GSH levels,
as well as CAT activities nearly those in the controls, indicating that
AVE have potentially reduced ROS-mediated oxidation of
Fig. 4. Synovial cytokine and chemokine concentrations. Levels of (A) TNFa, (B) IL-1b, (C) IFNg, (D) IL-6, (E) IL-12, (F) IL-10, (G) IL-8, and (H) MCP-1 in synovial tissues from mice as
determined by ELISA. Results were reproduced in three experiments. The results are obtained from three repeated experiments and the values are expressed as mean ± SD; (n ¼ 6/
group). *indicates signiﬁcant difference in comparison to NLD (control) (p < 0.05); #indicates signiﬁcant difference in comparison to AVE (100 mg/kg)-fed mice (p < 0.05); and,
i^ndicates signiﬁcant difference in comparison to CIA mice (p < 0.05).
Fig. 5. MPO activity in spleen and synovial tissue. MPO activity was analyzed as an index of neutrophil inﬁltration into the (A) spleen and (B) synovial tissues. The results are
obtained from three repeated experiments and the values are expressed as mean ± SD; (n ¼ 6/group). *indicates signiﬁcant difference in comparison to NLD (control) (p < 0.05);
#indicates signiﬁcant difference in comparison to AVE (100 mg/kg)-fed mice (p < 0.05); and, i^ndicates signiﬁcant difference in comparison to CIA mice (p < 0.05).
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also have attenuated the LPO content and SOD activities in liver,
spleen and synovial tissues signiﬁcantly (Figs. 6e8) in CIA mice.3.9. Effect of AVE on NO production in synovial tissues
NO production in the synovial tissues in mice with AVE treat-
ment was signiﬁcantly reduced in CIA mice (Table 3), indicating a
protective role of the AVE during chronic inﬂammation in synovial
tissue.3.10. AVE attenuated TLR-2 expression in synovial joints of CIA mice
Elevated TLR-2 expression in synovial tissues was observed in
CIAmice (Fig. 9, Panel A [lane 3] and Panel B [lane 3]). AVE (100mg/
kg) inhibited this increase in TLR-2 expression in the CIA mice
(Fig. 9, Panel A [lane 4]). AVE treatment at this level did not induce
any changes in control animals (Fig. 9, Panel A [lane 2] and Panel B
[lane 2]).4. Discussion
RA in mice is almost exactly mimicked by collagen-induced
arthritis, with neovascularization and pannus formation leading
to synovitis type of inﬂammation [27], instead of the basic differ-
ence in initiation of pathogenesis, i.e. in case of RA the individual
develops antibody against citrullinated peptides of vimentin and
ﬁbronectin, whereas in case of CIA, the antibody response is driven
against type II collagen, a component of diarthodial joint. In the
present study we have shown that oral administration of AVE to
mice provided protection against the progression of auto-immune
arthritis as indicated from the results of arthritic scoring, following
the booster injection with collagen-IFA which was observable from
the day 12 after booster immunization. Histopathological study of
joints also supported the fact that A. vasica provided signiﬁcant
resistance against bone damage during chronic inﬂammatory re-
actions, the fact further supported by attenuation of SGOTand SGPT
by AVE, the clinical markers for arthritis.
Collagen type II in emulsion with CFA activates both the cell-
mediated and humoral arms of the immune system that depends
Fig. 6. Anti-oxidant status in liver tissues. Levels of (A) GSH (in m mole/mg tissue protein), (B) LPO (in nmole/mg tissue protein), (C) SOD (U/mg tissue protein) and (D) catalase
activity (in mmole H2O2 consumed/min/mg tissue protein) in hepatic tissues of mice. The results are obtained from three repeated experiments and the values are expressed as
mean ± SD; (n ¼ 6/group). *indicates signiﬁcant difference in comparison to NLD (control) (p < 0.05); #indicates signiﬁcant difference in comparison to AVE (100 mg/kg)-fed mice
(p < 0.05); and, i^ndicates signiﬁcant difference in comparison to CIA mice (p < 0.05).
Fig. 7. Anti-oxidant status in spleen tissues. Levels of (A) GSH (in mmole/mg tissue protein), (B) LPO (in nmole/mg tissue protein), (C) SOD (U/mg tissue protein) and (D) catalase
activity (in mmole H2O2 consumed/min/mg tissue protein) in splenic tissues from mice. The results are obtained from three repeated experiments and the values are expressed as
mean ± SD; (n ¼ 6/group). *indicates signiﬁcant difference in comparison to NLD (control) (p < 0.05); #indicates signiﬁcant difference in comparison to AVE (100 mg/kg)-fed mice
(p < 0.05); and, i^ndicates signiﬁcant difference in comparison to CIA mice (p < 0.05).
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Fig. 8. Anti-oxidant status in synovial tissues. Levels of (A) GSH (in mmole/mg tissue protein), (B) LPO (in nmole/mg tissue protein), (C) SOD (U/mg tissue protein) and (D) catalase
activity (in mmole H2O2 consumed/min/mg tissue protein) in synovial tissues from mice. The results are obtained from three repeated experiments and the values are expressed as
mean ± SD; (n ¼ 6/group). *indicates signiﬁcant difference in comparison to NLD (control) (p < 0.05); #indicates signiﬁcant difference in comparison to AVE (100 mg/kg)-fed mice
(p < 0.05); and, i^ndicates signiﬁcant difference in comparison to CIA mice (p < 0.05).
Table 3
Synovial nitric oxide production (in mg/g of synovial tissue).
Sl. No. Groups NO level (in mg/g of tissue) (mean ± SD)
1. NLD (control) 19.61 ± 3.65
2. AVE (100 mg/kg) 21.39 ± 3.98
3. NLD þ CIA 92.62 ± 13.11*#
4. CIA þ AVE (50 mg/kg) 55.32 ± 9.21*#^
5. CIA þ AVE (100 mg/kg) 31.27 ± 6.18 ^
6. CIA þ AVE (200 mg/kg) 26.29 ± 5.19 ^
Effects of AVE on NO production in synovial tissues. Alterations in production of
nitric oxide (mg/g of tissue protein) in synovial tissues from all the six different
groups of animals. The results were reproduced in three repeated experiments.
Values are expressed as mean ± SD of six mice per group. P value less than 0.05 was
considered as signiﬁcant. *indicates signiﬁcant (P < 0.05) difference in comparison
to NLD (control), #indicates signiﬁcant difference (P < 0.05) in comparison to AVE
(100 mg/kg) fed mice and i^ndicates signiﬁcant difference (P < 0.05) in comparison
to CIA induced mice.
Fig. 9. TLR-2 expression in synovial joints of CIA mice. Synovial tissue homogenates
were prepared for the analysis of TLR-2 expression by immunoblot assay for samples
from CIA (A, upper panel) mice. Respective fold-changes in expression are shown in B
and C. All samples were probed with b-tubulin to assure equal protein loading in gels
occurred (A, lower panel). Expression of TLR-2 was measured in terms of fold-change
over control. Results were reproduced in three experiments. Values shown are
mean ± SD; (n ¼ 6/group). *indicates signiﬁcant difference in comparison to NLD
(control) (p < 0.05); #indicates signiﬁcant difference in comparison to AVE (100 mg/
kg)-fed mice (p < 0.05); and, i^ndicates signiﬁcant difference in comparison to CIA
mice (p < 0.05).
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vide cytokines, i.e. IL-2, IFN-g that are typically important for
triggering sufﬁcient inﬂammatory responses in the body. Immune
complexes deposited into the synovial joints elevate pro-
inﬂammatory cytokines in serum, through induction of mono-
nuclear cells [29]. In circulation these immune complexes can
stimulate peripheral PMNs and macrophages to secrete pro-
inﬂammatory cytokines, like TNF-a, via FcgRIIa on the macro-
phages [29]. In both ways, there is activation of synovial macro-
phages which ultimately results in increased production of TNF-a
and IL-1b, two key pro-inﬂammatory cytokines involved in RA
pathogenesis [30]. Besides TNF-a and IL-1b, other equally impor-
tant cytokines like IL-6, IL-12 and IL-15 are also produced by the
synovial macrophages, which are pro-inﬂammatory in nature. Among a number of different pro-inﬂammatory mediators, IL-6 in
particular can induce acute phase inﬂammatory response in
R. Adhikary et al. / Journal of Nutrition & Intermediary Metabolism 3 (2016) 1e1110hepatic tissues during CIA and results in an increment in the serum
levels of CRP, SAA, pentraxins and other inﬂammatory mediators
[31]. Serum CRP, a surrogate marker of disease severity that cor-
relates with ﬁnal outcome of arthritis [32,33] is also a potent
endogenous ligand for TLR-2 present on the surfaces of synovial
ﬁbroblasts, PMNs and macrophages [34], and it's transcription is
regulated by pro-inﬂammatory cytokines including IL-6 [35]. Since
regulation of TLR-2 expression has been correlated to protection in
many diseases, treatment of arthritic mice with AVE that affect CRP
and IL-6 could reasonably be expected to translate into clinical ef-
ﬁcacy against RA [36].
Serum concentration of CRP, the most common type of acute
phase proteins was tested in our experiments and was found to be
signiﬁcantly attenuated in case of CIA mice treated with AVE. This
explains protective role of AVE against liver damage and inﬂam-
matory reactions in hepatic tissues during pathogenesis of CIA.
TNF-a, IL-1b, IL-6 and IL-12 were also found to be attenuated with
AVE treatment when measured in serum as well as synovial tissues
of CIA mice. IL-10 is the most potent anti-inﬂammatory cytokine
and a chief regulator of arthritogenesis [37] which was also
elevated in serum and synovial joints after AVE treatment in CIA
mice. Elevation in myeloperoxidase activity from spleen and sy-
novial joints with concert to themarked reduction in IL-8 andMCP-
1, the two biologically important chemokines for PMNs and
monocytes in the synovial tissues in CIA mice treated with AVE
shows inhibitory potential of AVE against neutrophil and monocyte
inﬁltration in synovial joints.
Restored GSH level and attenuation of the lipid peroxide gen-
eration along with modulated enzymatic activities of superoxide
dismutase (SOD) and catalase (CAT) in liver, spleen and synovial
joints from CIA mice treated with AVE might dictate how the anti-
oxidant or radical scavenging activity of AVE attenuates chronic
inﬂammation in arthritic joints. TNF-a dependent NO production in
inﬂamed synovium has been described as a major cause of synovial
hyperplasia in RA through onset of hypoxia mediated angiogenesis
[38] and the suppression of NO production in synovial joints in our
study might have been resulted from decreased TNF-a and iNOS
expression in CIA mice treated with AVE.
Amongst a number of different endogenous ligands, there are
two such molecules that primarily activate TLR-2; gp96, a compo-
nent of synovial lining and serum amyloid A, an acute phase protein
released during liver inﬂammatory responses [39]. In our study we
found suppression of TLR-2 expression in arthritic joints from CIA
mice treated with AVE. To explain the mechanism how AVE
dampened TLR-2 expression, we can speculate from the MPO ac-
tivity and CRP level in CIA mice which shows a marked reduction
after AVE treatment. MPO activity as a direct marker of neutrophil
accumulation, along with local chemokines (IL-8 and MCP-1)
clearly depicts a signiﬁcant decrease in neutrophil in synovial
joints from CIA mice treated with AVE. AVE, prevents oxidative
stress in liver, and therefore is also expected to suppress the acute
phase response in liver and CRP level in serum. Therefore,
decreased PMN inﬁltration in synovial joints that is directly pro-
portional to the amount of TLR-2 expressed in the synovial tissue
along with decreased CRP, the potent activator of TLR-2 mediated
signaling pathway can be correlated to the suppression of TLR-2
expression from arthritic joints in CIA mice treated with AVE.
Therefore, suppression of TLR-2 expression in arthritic joints in
collagen induced arthritic mice after treatment with AVE could be a
therapeutic approach.
In an unpublished observation GCeMS study conﬁrmed abun-
dance of diterpene such as phytols, hexadecanoic acids, alkaloids
such as 2'-(trimethylsiloxy)-2emethyl-7-phenylindole - 1-H -
pyrrolo [2, 3-b] pyridine - 1- propionitrile and glucosinolates like
desulphosinigrin which was identiﬁed in the AVE. However, theeffect shown by AVE that ameliorates CIA induced inﬂammation
and progressive bone damage is an outcome of a cumulative effect
of all these bioactive compounds, therefore further studies are
warranted on these chemical constituents frommethanol extract of
leaves of A. vasica after purifying them and administering them
separately in animal models with respect to collagen induced
arthritis.
5. Conclusion
The present study has demonstrated that the administration of
methanolic extract of A. vasica leaf improves against chronic
inﬂammation during deleterious progression of RA by down-
regulating synovial TLR-2 expression and pro-inﬂammatory
mediator release and it can be used in pharmacological research
for future drug discovery and development in the ﬁelds of
rheumatology.
Conﬂict of interest
The authors declare no conﬂicts of interest. The authors alone
are responsible for the content of this manuscript.
Acknowledgements
This work was supported and funded by Department of Science
and Technology (DST), Govt. of West Bengal, Calcutta, India [Sanc-
tion number. 297(Sanc)/ST/P/S&T/9G-08/2012].
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.jnim.2015.11.001.
References
[1] A. Kaur, P. Nain, J. Nain, Herbal plants used in treatment of rheumatoid
arthritis: a review, Int. J. Pharm. Pharm. Sci. 4 (2012) 44e57.
[2] E. Choy, Understanding the dynamics: pathways involved in the pathogenesis
of rheumatoid arthritis, Rheumatology 51 (2012) 3e11.
[3] R.K. Kim, T.Y. Chung, H. Shin, Red ginseng saponin extract attenuates murine
collagen-induced arthritis by reducing pro-inﬂammatory responses and ma-
trix metallo-proteinase-3 expression, Biol. Pharm. Bull. 33 (2010) 604e610.
[4] D. Khanna, G. Sethi, K.S. Ahn, M.K. Pandey, A.B. Kunnumakkara, B. Sung,
A. Aggarwal, B.B. Aggarwal, Natural products as a gold mine for arthritis
treatment, Curr. Opin. Pharmacol. 7 (2007) 344e351.
[5] G.R. Burmester, E. Feist, T. Dorner, Emerging cell and cytokine targets in
rheumatoid arthritis, Nat. Rev. Rheumatol. 10 (2014) 77e88.
[6] J.A. Hinson, D.W. Roberts, L.P. James, Mechanisms of acetaminophen-induced
liver necrosis, in: Handbook of Experimental Pharmacology, Springer-Verlag
Berlin Heidelberg, New York, 2010, pp. 369e405.
[7] A. Mahajan, V.R. Tandon, Antioxidants and rheumatoid arthritis, J. Ind.
Rheumatol. Assoc. 12 (2004) 139e142.
[8] S. Jaswal, H.C. Mehta, A.K. Sood, J. Kaur, Antioxidant status in rheumatoid
arthritis and role of antioxidant therapy, Clin. Chim. Acta 338 (2003) 123e139.
[9] T. Jayakumar, M. Ilayaraja, M.P. Sridhar, S. Sivalokanathan, T.R. Prasad,
M.P. Balasubramanian, Protective effect of Adhatoda vasica on D-galactos-
amine induced liver damage in rats with reference to lipid peroxidation and
antioxidant status, J. Natur. Remed 9 (2009) 91e98.
[10] B. Singh, R.A. Sharma, Anti-inﬂammatory and antimicrobial properties of
pyrroloquinazoline alkaloids from Adhatoda vasica Nees, Phytomedicine 20
(2013) 441e445.
[11] W.P. Arend, The innate immune system in rheumatoid arthritis, Arth. Rheum.
44 (2001) 2224e2234.
[12] G. Falgarone, O. Jaen, M.C. Boissier, Role for innate immunity in rheumatoid
arthritis, Jt. Bone. Spine 72 (2005) 17e25.
[13] A. Iwasaki, R. Medzhitov, Regulation of adaptive immunity by the innate
immune system, Science 327 (2010) 291e295.
[14] Q. Huang, R.M. Pope, Toll-like receptor signaling: a potential link among
rheumatoid arthritis, systemic lupus, and atherosclerosis, J. Leuko. Biol. 88
(2010) 253e262.
[15] M. Iwahashi, M. Yamamura, T. Aita, A. Okamoto, A. Ueno, N. Ogawa, S. Akashi,
K. Miyake, P.J. Godowski, H. Makino, Expression of Toll-like receptor 2 on
CD16þ blood monocytes and synovial tissue macrophages in rheumatoid
R. Adhikary et al. / Journal of Nutrition & Intermediary Metabolism 3 (2016) 1e11 11arthritis, Arth. Rheum. 50 (2004) 1457e1467.
[16] L.K. Sorensen, A. Havemose-Poulsen, S.U. Sonder, K. Bendtzen, P. Holmstrup,
Blood cell gene expression proﬁling in subjects with aggressive periodontitis
and chronic arthritis, J. Periodontol. 79 (2008) 477e485.
[17] H.C. Oliveira, M.P. Dos-Santos, R. Grigulo, L.L. Lima, Antidiabetic activity of
Vatairea macrocarpa extract in rats, J. Ethnopharmacol. 115 (2008) 515e519.
[18] D.D. Brand, K.A. Latham, E.F. Rosloniec, Collagen-induced arthritis, Nat. Protoc.
5 (2007) 1269e1275.
[19] M.M. Bradford, A rapid and sensitive method for the quantitation of micro-
gram quantities of protein utilizing the principle of protein-dye binding, Anal.
Biochem. 72 (1976) 248e254.
[20] A. Majhi, K. Kundu, R. Adhikary, M. Banerjee, S. Mahanti, A. Basu, Combination
therapy with ampicillin and azithromycin in an experimental pneumococcal
pneumonia is bactericidal and effective in down regulating inﬂammation in
mice, J. Inﬂamm. 11 (2014) 5e22.
[21] S. Reitman, A. Frankel, Colorimetric method for the determination of serum
glutamic oxalacetic and glutamic pyruvic transaminases, Am. J. Clin. Pathol. 28
(1957) 56e63.
[22] S. Majumdar, K. Dutta, S.K. Manna, A. Basu, B. Bishayi, Possible protective role
of chloramphenicol in TSST-1 and coagulase-positive Staphylococcus aureus-
induced septic arthritis with altered levels of inﬂammatory mediators,
Inﬂammation 34 (2011) 269e282.
[23] J. Sedlak, R.H. Lindsay, Estimation of total, protein-bound, and non protein
sulfhydryl groups in tissue with Ellman's reagent, Anal. Biochem. 25 (1968)
192e205.
[24] P. Mal, D. Ghosh, D. Bandyopadhyay, K. Dutta, B. Bishayi, Ampicillin alone and
in Combination with riboﬂavin modulates Staphylococcus aureus induced
septic arthritis in mice, Ind. J. Exp. Biol. 50 (2012) 677e689.
[25] K. Dutta, D. Nandi, B. Bishayi, Repeated systemic Escherichia coli infection
enhances anti-oxidant response in hypercholesterolemic mice inducing car-
diovascular inﬂammation, Inﬂammation 32 (2009) 89e98.
[26] A. Majhi, R. Adhikary, A. Bhattacharyya, S. Mahanti, B. Bishayi, Levoﬂoxacin-
Ceftriaxone combination attenuates lung inﬂammation in a mouse model of
bacteremic Pneumonia caused by multidrug- resistant Streptococcus pneu-
moniae via inhibition of cytolytic activities of pneumolysin and autolysin,
Antimicrob. Agents. Chemother. 58 (2014) 5164e5180.
[27] E. Lubberts, W.B. van den Berg, Cytokines in the pathogenesis of rheumatoid
arthritis and collagen-induced arthritis, in: Cytokines and Chemokines inAutoimmune Disease, E-Publishing Inc, USA, 2003, pp. 194e203.
[28] B. Catchpole, N.A. Staines, A.S. Hamblin, Antigen presentation of type II
collagen in rats, Clin. Exp. Immunol. 125 (2001) 478e484.
[29] L. Mathsson, J. Lampa, M. Mullazehi, J. R€onnelid, Immune complexes from
rheumatoid arthritis synovial ﬂuid induce FcgRIIa dependent and rheumatoid
factor correlated production of tumour necrosis factor-a by peripheral blood
mononuclear cells, Arth. Res. Ther. 8 (2006) 1e10.
[30] R.O. Williams, L. Marinova-Mutafchieva, M. Feldmann, R.N. Maini, Evaluation
of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison
with combined anti-TNF-alpha/anti-CD4 therapy, J. Immunol. 165 (2000)
7240e7245.
[31] A.K. Abbas, A. Lichtman, S. Pillai, Immunity to microbes, in: Cellular and
Molecular Immunology, Elsevier, Philadelphia, 2007, pp. 356e358.
[32] T. van den Broek, J.R. Tesser, S. Albani, The evolution of biomarkers in rheu-
matoid arthritis: from clinical research to clinical care, Exp. Opin. Biol. Ther. 8
(2008) 1773e1785.
[33] J. Devlin, A. Gough, A. Huissoon, P. Perkins, R. Holder, R. Reece, V. Arthur,
P. Emery, The acute phase and function in early rheumatoid arthritis. C-
reactive protein levels correlate with functional outcome, J. Rheumatol. 24
(1997) 9e13.
[34] R.L. He, J. Zhou, Z.C. Hanson, J. Chen, N. Cheng, D.R. Ye, Serum amyloid A in-
duces G-CSF expression and neutrophilia via Toll-like receptor-2, Blood 113
(2009) 429e437.
[35] P.T. Lukey, H.C. Perry, S. Yang, S. Parry, M.C. Dickson, V.H. Norris, P.G. Russell,
M. Watissee, I. Rioja, K.P. Ray, S. Crowe, M. Binks, Single doses of p38 MAP
kinase inhibitors or prednisolone affect CRP and IL-6 in patients with active
rheumatoid arthritis, Open. J. Immunol. 2 (2012) 85e97.
[36] M.B. Pepys, G.M. Hirschﬁeld, C-reactive protein: a critical update, J. Clin.
Invest. 111 (2003) 1805e1812.
[37] L.A. Joosten, E. Lubberts, P. Durez, M.M. Helsen, M.J. Jacobs, M. Goldman,
W.B. van den Berg, Role of interleukin-4 and interleukin-10 in murine
collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-
10 treatment on cartilage destruction, Arth. Rheum. 40 (1997) 249e260.
[38] F. Bao, P. Wu, N. Xiao, F. Qiu, Q.P. Zeng, Nitric oxide-driven hypoxia initiates
synovial angiogenesis, hyperplasia, and inﬂammatory lesions in mice, PLoS.
One 7 (2012) e34494.
[39] N. Cheng, R. He, J. Tian, P.P. Ye, R.D. Ye, Cutting edge: TLR-2 is a functional
receptor for acute-phase serum amyloid A, J. Immunol. 181 (2008) 22e26.
